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ORIGINAL RESEARCH
Background: Nearly 5 million children in the United States are affected by asthma, which is
more than 5% of the population younger than 18 years. In children four years or younger, the
prevalence increased 160% from 1980 to 1994. There are several effective drugs that relieve
the symptoms of asthma and others are currently being developed, but even when these
medications are prescribed, they may be underutilized because parents fear the possibility of
adverse events. Up to now there is no knowledge which are the main drivers of caregiver’s
preferences for a safe and effective medication for preschool children in general. The study
population was caregivers with children aged 4 years or below. Sample size was 42; results
were checked by Monte Carlo simulation.
Material and methods: For a conjoint analysis a status quo treatment and hypothetical
treatment options were defined by four attributes: Episode-free days, risk of exacerbation,
information available for the long-term impact of the treatment, and out-of-pocket expenses.
It was possible to use the status quo as the reference scenario, permitting to couch this ranking
in terms of a decision to purchase the product. Relative importances for each product attribute
as well as utility estimations for each attribute level were calculated.
Results and discussion: The overall result was that the most important feature for an asthma
treatment, in this study, was the attribute of episode-free days. On a scale from 0 to 100 this
attribute got the calculated relative importance of 44.2. In contrast to this finding is the relative
importance of the attribute EXACERBATION, which only reached 16.2, which is the most
unimportant attribute of the attributes offered. Even the variable INFORMATION available
on long-term effects in children between 4 years and 14 years of age was more important than
the side effects (19.2). Out-of-pocket expenses per month were the second most (relative)
important attribute (20.5).
Keywords:  utility, conjoint analysis, preference study, health economics, discrete-choice
analysis
Introduction
Asthma is a chronic disease that effects between 9 and 12 million persons in the US
(Weiss et al 1992) and is the most common chronic disease of childhood (CDC
2000). Nearly 5 million children in the US are affected by asthma, which is more
than 5% of the population younger than 18 years (Adams and Marano 1994). It is the
leading cause of lost school days in children (Taylor and Newacheck 1992; NHDS
1993). In children four years or younger, the prevalence increased 160% from 1980
to 1994. To avoid the missing school days preschool children should be treated in the
most effective way as possible. There are several effective drugs that relieve the
symptoms of asthma and others are currently being developed but even when these
medications are prescribed, they may be underutilized because parents fear the
possibility of adverse events and long-term effects. Up to now there is no knowledge
which are the main drivers of caregiver’s preferences for a safe and effective
medication for preschool children in general.
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Asthma or wheezing conditions was not explicitly
defined. Respondents were screened based on the asthma
medication that the child is currently taking for the treatment
of the condition. Severity of asthma/wheezing condition was
identified by applying the “Evaluation of a short form for
measuring health-related quality of life among pediatric
asthma patients”.
For an economic evaluation (such as a preference study)
of treatments in diseases such as asthma, where a substantial
impact is on quality of life rather than survival, it is crucial
to be able to incorporate the effects of the new therapies on
quality of life and include those effects in the economic
evaluation. Within healthcare there is substantial evidence
to suggest that, in addition to the treatment outcome (that
is, the effectiveness), other aspects of the process of
receiving treatment are also important for individuals (Ryan
and Hughes 1997; Balsbaugh et al 1999; Ratcliffe and
Buxton 1999; Ryan 1999; Johansson et al 2004). Conjoint
analysis was originally developed for market research into
consumer preferences, and is a method that investigates the
relative importance of groups of attributes, eg, products with
certain properties or more abstract concepts such as
treatment procedures (Green and Rao 1971; Srinivasan and
Shocker 1973). It has been applied to various aspects of
healthcare (see Ryan 1996; Szeinbach et al 1999). The
method can thus be used to analyze patient preferences for
various treatment alternatives.
No asthma treatment regimen is likely to have all the
attributes that patients would ideally like; for example, a
regimen might be highly effective (desirable) but expensive
(undesirable). Conjoint analysis provides a method of
“trading off” desirable attributes against undesirable ones,
and assessing which attributes are most important in
determining the patient preferences for one regimen over
another. The target population of this study is preschool
children with a maximum age of 4 years. Obviously the
possibility of asking the children was naturally limited and
hence the caregivers answered for them.
The purpose of this study was to evaluate, using conjoint
analysis, asthma patients’ preferences for different aspects
of asthma treatment, including efficacy (episode-free days),
side effects (risk of exacerbation), available information by
the Food and Drug Administration (FDA) about long-term
effects, and out-of-pocket expenses. The relative importance
was evaluated for each of the described attributes.
Materials and methods
The methods used for the discrete choice part of this study
were already explained in a recent paper (Walzer and
Zweifel 2007). The study protocol was conducted in
accordance with the Declaration of Helsinki and approved
by local ethics committees, and all participants gave written
informed consent.
It is assumed that the preferences of caregivers of
preschool children with asthma could be taken as
approximations for the utility of their child for a given
treatment. If the caregiver is a pure altruist with respect to
the child, ie, cares for the child, but respects the child’s
preferences, the caretaker’s responses will reflect the child’s
preferences. For the present analysis caregivers were asked
to choose between two hypothetical asthma treatments for
their child. The decision was based on a status quo treatment
versus a new (hypothetical) treatment with changed attribute
levels. Possible attributes and their levels were tested in
various face-to-face interviews with caregivers in autumn
2005. Potential and actual study participants were contacted
based on information from a consumer database in the US.
The tested attributes were ease of handling, efficacy
(episode-free days), time for administration, number of
administrations per day, side effects (risk of asthmatic
exacerbation), available information by the FDA
(information on long-term effects in children between 4 and
14 years of age), as well as expenses. This pre-test was
deducted mainly as qualitative interviews with seven
applicants (see Table 1). It was found that the main attributes
for the treatment of asthma were expenses, episode-free
days, side effects, and available information by the FDA.
Pre-test interviews resulted in the fact that the main
attributes for the treatment of asthma were expenses,
episode-free days, side effects, and available information
by the FDA (Walzer and Zweifel 2007).
In conjoint analysis, several attributes of treatment are
selected and a range of possible values (“levels”) are defined
for each attribute (Ben Akiva and Lerman 1985). These are
used to create a number of treatment concepts, each with
different levels for the various attributes. The levels of
attributes were defined as follows (see Table 1): ‘Episode-
free days’ (FREEDAYS), symbolizing the change in the risk
to develop asthma attacks from an unknown individual level,
takes on changes from 180 days (baseline [Pauwels et al
1997]) to 200 and 220 days per year as well as a possible
decrease in change to 160 and 140 days per year.
‘Exacerbation’ (EXACERBATION), defined as developingTherapeutics and Clinical Risk Management 2007:3(1) 169
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mild or moderate exacerbation, varies between levels of 6%,
10%, and 16%. A recent study with adults has shown that
mild to moderate asthmatic patients are very much affected
by their disease and patient’s utility was decreasing when
developing an exacerbation (Andersson et al 2003). It is
assumed that these findings are also valid in preschool
children. For the FDA ‘information’ on long-term effects
(INFORMATION) in children between 4 and 14 years of
age, two levels were used: Availability or nonavailability.
Other studies have shown that caregivers could be concerned
about the missing long-term effects of asthma treatment in
preschool children (de Jongste et al 2002). The ‘out-of-
pocket cost’ (EXPENSES) per month ranges from $10, $30,
to $50. Status quo treatment (see Table 2) was defined as
having 180 episode-free days per year and a risk to develop
a mild or severe exacerbation of 10%. Information by the
FDA is available and the monthly out-of-pocket expenses
are $20.
Since the second and the last attributes have 3 levels
each, while FREEDAYS has 4 and INFORMATION has 2,
the number of scenarios amounts to a total of 72 (=
4*3*2*3). Techniques have been developed to reduce the
number of possible scenarios while still being able to infer
utilities for all combinations of levels of the attributes
(Louviere et al 2000). Using the ORTHOPLAN procedure,
which implicitly assumes a linear utility function,
programmed in the software package SPSS (SPSS Inc,
Chicago, Illinois, USA), the design was reduced to 16
scenarios. All study participants had to answer these 16
variants as well as two hold-out cards whereas the scenarios
were randomly assigned to take care of a possible question
ordering bias (Mitchell and Carson 1989). With regard to
each variant, respondents had to indicate whether or not
they would choose the treatment and would pay the monthly
out-of-pocket expenses (see Appendix A1 for a sample card
presented to study participants).
Results
Descriptive statistics
Descriptive statistics of the caregivers with regard to the
dependent and explanatory variables are reported in Table
3. Nearly all caregivers who took part in the survey were
female (92.9%). The average of the respondents have one
child. Caregivers were also asked how confident they are
in knowing what they do when they are thinking about their
overall ability to take care of their family’s general health:
eating right, getting check-ups, taking medicine, or deciding
when to see the doctor. Within the whole population, 42.9%
agreed with the statement of feeling “Very confident” and
another 26.7% agreed with the statement of feeling
”Extremely confident”. Summarized, 31% felt fairly and/
Table 1 Product attributes and levels retained in the main survey
Attributes Label Levels Value
labels
Episode-free days FREEDAYS Increase from 180 to 200 episode-free days per year 200
Increase from 180 to 220 episode-free days per year 220
Decrease from 180 to 1600 episode-free days per year 180
Decrease from 180 to 140 episode-free days per year 140
Exacerbation EXACERBATION Risk of EXACERBATION: 6% of patients develop a mild to severe EXACERBATION 6
Risk of EXACERBATION: 10% of patients develop a mild to severe EXACERBATION 10
Risk of EXACERBATION: 16% of patients develop a mild to severe EXACERBATION 16
Information about INFORMATION INFORMATION available on long-term effects in children between 4 years and 1
long-term effects by 14 years of age
the FDA available No INFORMATION available on long-term effects in children between 4 years and 2
14 years of age
Out-of-pocket EXPENSES $10 per month 10
EXPENSES $30 per month 30
$50 per month 50
Abbreviations: FDA, Food and Drug Administration.
Table 2 Status quo treatment: definition by attribute levels
Attributes Levels
Episode-free days 180 episode-free days per year
EXACERBATION Risk of EXACERBATION: 10% of
patients develop a mild to severe
EXACERBATION
INFORMATION availability INFORMATION available on long-term
effects in children between 4 years and
14 years of age
Out-of-pocket EXPENSES $20 per monthTherapeutics and Clinical Risk Management 2007:3(1) 170
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Table 3 Descriptive statistics of caregivers
Percent Cumulative
 percentage
Gender
Female 92.9
Age
<30 years 28.6
30–39 years 42.8 71.4
40–49 years 19.1 90.5
>50 years 9.5 100
Number of children ≤ ≤ ≤ ≤ ≤4 years
1 child 73.8
2 children 26.2 100
Rating of healthcare
Fairly/somewhat confident 31.0
Very/extremely confident 69.0 100
Number of children with diagnosed
asthma and/or wheezing conditions
1 child 73.8
2 children 26.2 100
Relationship to children
Mother or female guardian 85.7
Father or male guardian 7.1 92.9
Grandparent 7.1 100
Level of education
High school graduate (or lower) 11.9
Some college 31.0 42.9
Associate/Bachelor’s degree 40.5 83.3
Postgraduate school 14.3 97.6*
Current employment situation
Working full-time 40.5
Working part-time 11.9 52.4
Homemaker 45.2 97.6**
Annual household income in 2004
<US$25 000 4.8
US$25 000–49 999 45.2 50.0
US$50 000–74 999 19.0 69.0
>US$75 000 23.8 92.9***
Smoking
Smoker 28.6
Nonsmoker 71.4
Severity estimation by caregiver
Very mild 21.4
Mild 35.7 57.1
Moderate 40.5 97.6
Severe 2.4 100
Severity diagnosis by physician
Mild 35.7
Moderate 40.5 76.2
Severe 4.8 81.0
Doctor never told me the severity 19.9 100
Compliance estimation for other
caregivers
<20% 54.8
20%–39% 23.8 78.6
40%–59% 7.1 85.7
>60% 14.3 100
Note: *Other education: 2.4%; **Retired: 2.4%; ***Declined to answer: 7.1%;
****Don’t know: 2.4%
Table 3 Continued
Percent Cumulative
 percentage
Own compliance estimation
<10% 76.2
10%–19% 11.9 88.1
20%–29% 4.8 92.9
>30% 7.1 100
Children characteristics
Age
≤2 years (child 1) 33.3
≤2 years (child 2) 0
Gender
Female (child 1) 35.7
Female (child 2) 66.7
Race
White 88.1
Black 4.8 92.9
Other 7.1 100
Medications currently taken (more than one drug could be
chosen)
Accolate 2.4
Advair 2.4
Flovent 7.1
Pulmicort Respules 28.6
Singulair 76.2
Prevalence of asthma 88.1
Prevalence of wheezing conditions 26.2
Prevalence of allergies 71.4 —
Cough in last 4 weeks
Never 14.3
A few days 31.0 45.3
Some days 23.8 69.1
Most days 19.0 88.1
Every day 11.9 100
Wheezing conditions in last 4 weeks
Never 26.2
A few days 33.3 59.5
Some days 35.7 95.1
Every day 2.4 97.6****
Shortness of breath in last 4 weeks
Never 57.1
A few days 16.7 73.8
Some days 19.0 92.8
Most of the days 4.8 97.6****
Asthma attacks in last 4 weeks
Never 85.7
A few days 9.5 95.2
Some days 2.4 97.6
Most of the days 2.4 100
Number of asthma attacks in last 4 weeks
0 16.7
1 attack 50.0 66.7
2 attacks 16.7 83.3
6 attacks 16.7 100
Awakened in last 4 weeks due to asthma/wheezing conditions
Never 38.1
A few days 40.5 78.6
Some days 16.7 95.2
Most of the days 4.8 100Therapeutics and Clinical Risk Management 2007:3(1) 171
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or somewhat confident and 69% of caregivers felt very and/
or extremely confident.
In 18% of cases, the doctor never told the caregiver the
asthma severity diagnosis of their child. Of caregivers,
21.4% rated the severity of their child as very mild, whereas
no physician diagnosed a child with that rate. Differences
in diagnosing severe asthma could be detected: 4.8% of
physicians diagnosed children as having severe asthma
whereas only 2.4% of caregivers made the same diagnosis.
Caregivers were also asked about their estimation of how
many caregivers (in general) forget to provide the asthma
medication for their child during a week due to several
reasons (job stress, care for other children, etc.) in one week
on average. In various studies it turned out that up to 95%
of caregivers (on average around 50%) don’t give the
medication in the right way (not regularly, wrong dosage,
etc.) (Gibson et al 1995; Moy et al 2004). Study respondents
estimated that 16.7% of other caregivers never forget to
administer medication per week. It was estimated by 54.8%
of study respondents that a maximum of 19% forget to
medicate their child. But when asking in how many cases
the caregivers themselves forget it, 88.1% of study
respondents said that they themselves forget to ask at a
maximum of 19%. When estimating for other caregivers,
the cumulative of 88% is reached for around 69% of
caregivers who will forget to offer the (correct) treatment,
which is nearly the number that could be found in the
literature.
The medications children were currently taking for the
treatment of asthma and/or wheezing conditions are
distributed in this sample as follows, whereas more than
one drug could be taken for treatment: 76.2% are taking
Singulair; 28.6% Pulmicort Respules; 7.1% Flovent;
Accolate; and Advair are taken by 2.4% respectively. During
the last 4 weeks in advance of the survey, 23.8% of children
have experienced cough on some days whereas 19%
experienced this complication most days. Cough was
experienced every day by 11.9% of children. The condition
wheezing was less often experienced every day (2.4%) but
nearly 33% experienced wheezing for a few days in the last
4 weeks. Caregivers reported that 57.1% of their children
never had shortness of breath, but 19% reported that their
children experienced that symptom some days in the last
month. Asthma attacks in this study population were not
that frequent (never experienced in the last 4 weeks: 85.7%)
with experiences of this symptom a few days in 9.5%. Of
those who experienced asthma attacks, 50% had one attack
in the last month, 16.7% had two, and another 16.7% had
six asthma attacks. The possibility of awakening during the
night due to asthma/wheezing conditions, such as asthma
attacks, etc., was relatively frequent but not that severe:
38.1% never awakened, 40.5% awakened a few nights,
16.7% some nights, but also 4.8% awakened each night.
Most or all the time treatment choices were offered to
the caregivers by 52.4% of pediatricians of these children
(Table 4). While they were doing so, the physicians also
discussed the pros and cons of the offered/suggested
treatments. After discussions with caregivers, they stated
that pediatricians take their preferences into account when
making treatment decisions for their child’s asthma or
wheezing conditions care. This could be taken as an
indication that these caregivers should be interested in
available information by the FDA on long-term effects.
Additionally, 85.7% of caregivers reported to follow the
asthma or wheezing conditions medication schedule given
to them by their child’s doctor or nurse. On the other hand,
around 90% mentioned that they provide medications to
their child when they feel it was appropriate.
Table 4 Treatment behavior of caregivers
Percent Cumulative
percent
Physician offers treatment choices in child’s asthma or
wheezing conditions care
All of the time 28.6
Most of the time 23.8 52.4
Some of the time 28.6 81.0
A little of the time 2.4 83.3
None of the time 16.7 100
Physician discusses the pros and cons of each treatment
choice with you
All of the time 35.7
Most of the time 33.3 69.0
Some of the time 9.5 78.6
A little of the time 7.1 85.7
None of the time 14.3 100
Physician takes your preferences into account when making
treatment decisions for your child
All of the time 35.7
Most of the time 40.5 76.2
Some of the time 9.5 85.7
A little of the time 4.8 90.5
None of the time 9.5 100
I follow the asthma or wheezing conditions medication
schedule given to me by my child’s doctor or nurse
Yes 85.7
No 14.3 100
I provide asthma or wheezing conditions medication(s) to my
child when I feel is appropriate
Yes 90.5
No 9.5 100Therapeutics and Clinical Risk Management 2007:3(1) 172
Walzer
Conjoint analysis
Results from the discrete choice decisions served as a basis
for a conjoint analysis (Green and Rao 1971). Relative
importance for each product attribute as well as utility
estimations for each attribute level was calculated.
For the caregivers, the key attribute for an asthma drug
for the treatment of childhood asthma is FREEDAYS. On a
scale from 0 to 100 this attribute got the calculated relative
importance of 44.2 (Figure 1). In contrast to this finding is
the relative importance of the attribute EXACERBATION,
which only reached 16.2, which is the most unimportant
attribute of the attributes offered. Even the variable
INFORMATION available on long-term effects in children
between 4 years and 14 years of age was more important
than the side effects (19.2). Out-of-pocket expenses per
month were the second most (relative) important attribute,
whereas it was only slightly more important than the attribute
INFORMATION (20.5).
The utilities for the efficacy attribute (FREEDAYS) are
positive for the increase of episode-free days and negative
for the decrease of episode-free days (Table 5). However,
the utility is not increasing with the increasing number of
episode-free days. With decreasing episode-free days, the
utilities are also decreasing. The utilities for the increasing
out-of-pocket EXPENSES were decreasing with the
growing costs. Furthermore the utility for the available
information is positive and vice versa.
The conjoint analysis’ findings were also tested for its
possibilities to predict the observed values: Pearson’s R was
relatively good (0.73) as well as Kendall’s tau (0.54),
whereas both measures were highly significant for the
correlation between the observed and predicted values
(Table 6). Furthermore Kendall’s tau for the hold-out cards
is 1.
Sensitivity analysis
Due to budget restrictions, only 42 respondents could be
included in this survey. However, to improve the validity
and significance of the study, the data have also been
simulated by 100 Monte Carlo iterations (Vose 2001). Monte
Carlo simulations are reproducing data dependent on the
input data and their corresponding distributions. In this way
it can be checked how sensitive the underlying base data
are to changes in the inputs. For the simulation the binomial
distribution was assumed for the simulation of the outcome
“Scenario”. For the caregiver’s socioeconomic
characteristics a beta-pert distribution was assumed to stay
within the calculated ranges of the parameters given by the
study participants (Drummond et al 2005). It turned out that
the ranking for the relative importance of the four attributes
is not changed when using 100 iterations (Figure 1), which
was used as having 100 respondents. This procedure is state-
of-the-art for checking uncertainty around the data in
economic evaluation studies (Drummond et al 2005).
Discussion
This study has investigated patient preferences for different
attributes of asthma treatment in preschool children. The
overall result was that the most important feature for an
asthma treatment in this study was the episode-free days.
The major criticism about the study is the small sample
size of 42 respondents. Due to this fact, the results could be
biased due to outliers who could be overweighed. Within a
larger population the results could maybe more smoothed
and outliers would not be overweighed as can be assumed
in a small sample size. However in a Monte Carlo simulation
study, which was done along that original study using the
study data, it turned out that the conjoint results are relatively
stable and could give a first impression about preferences
for a treatment within such a special population like
caregivers of asthmatic children.
Table 5 Conjoint analysis: Utility estimations (Base Case)
 Utility Standard
Estimate Error
FREEDAYS
Increase episode-free days 180 to 200 0.057 0.038
Increase episode-free days 180 to 220 0.039 0.038
Decrease episode-free days 180 to 160 -0.045 0.038
Decrease episode-free days 180 to 140 -0.051 0.038
EXACERBATION
6% develop an EXACERBATION 0.036 0.027
10% develop an EXACERBATION 0.071 0.053
16% develop an EXACERBATION 0.107 0.080
INFORMATION
INFORMATION available -0.060 0.044
No INFORMATION available -0.119 0.088
EXPENSES
$10 -0.018 0.027
$30 -0.037 0.053
$50 -0.055 0.080
(Constant) 0.116 0.096
Table 6 Conjoint analysis: Correlations between observed and
estimated preferences
 Value Sig.
Pearson’s R 0.703 0.001
Kendall’s tau 0.543 0.002
Kendall’s tau for holdouts 1.000 0.0Therapeutics and Clinical Risk Management 2007:3(1) 173
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The attribute EXACERBATION turned out to be the
most unimportant attribute in the base analysis when
comparing with the variable INFORMATION available on
long-term effects in children between 4 years and 14 years
of age. This finding could possibly be explained given that
caregivers weight the possible long-term effects, which
should be explained by the FDA information, higher than
the short-term side effects like the risk of an asthmatic
exacerbation. The utilities for each attribute level was in
the range as expected with two exceptions: the utility for
the efficacy attribute is not increasing with the increasing
number of episode-free days. One possible explanation for
this could be that the caregivers did not believe that the
efficacy would increase by nearly 22% (possible theoretical
misspecification bias [Mitchell and Carson 1989]) from 180
days to 220 days. With decreasing episode-free days, the
utilities are also decreasing. Additionally, the finding for
the utilities of the risk of exacerbations was also
counterintuitive: the higher the probability of an
exacerbation, the higher the utility. The relative low
importance of that attribute could lead to that finding, ie,
that other positive impacts traded out the negative impact
of this attribute. Additionally, only few children experienced
(very) often shortness of breath or much asthma attacks in
the last four weeks in advance of the study. Maybe caregivers
are less risk-averse on this attribute when comparing it with
the other three. This could be a major caveat of the study,
however, the aim of a discrete choice analysis is to have
respondents switching between the status quo and the
offered (hypothetical) products to calculate the relative
importance for the various attributes (Szeinbach et al 1999).
In this application the discrete-choice conjoint analysis
requires respondents only to indicate whether they prefer
one scenario over another. Moreover, it was possible to use
the status quo as the reference scenario, permitting to couch
this ranking in terms of a decision to purchase the product.
The conjoint method has been used for decades in other
research disciplines, notably consumer market research, but
has only recently started to be used to study asthma. Osman
et al (2001) used conjoint analysis to rank asthma symptoms.
Another study (Gibson et al 1995) investigated preferences
for a limited number of aspects (need for blood test
monitoring, frequency of dosing, and route of
administration) for asthma controller medication. To our best
knowledge this study is the first one, which analyzed the
impact of various treatment attributes on the relative
importance of caregivers for their preschool children’s
asthma treatment. Obviously the sample size is relatively
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Base Case
100 iterations
Base Case 100 iterations
FREEDAYS 44.189 40.303
EXACERBATION 16.181 16.667
INFORMATION 19.153 17.362
EXPENSES 20.477 25.668
Figure 1 Relative importance of factors for treatment of pediatric asthma and/or wheezing conditions. Base Case based on the real number of respondents in
comparison to 100 iterations from a Monte Carlo simulation.Therapeutics and Clinical Risk Management 2007:3(1) 174
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small due to budget restrictions. The results should be
important in the ranking of attribute importance in preschool
children in chronic diseases. Furthermore, the children who
participated in the present study are not representative and
thus the generalizability of the results is uncertain; eg, the
children were typically first-born children with very mild
asthma and working mothers with university degrees. Hence
the following findings have to be interpreted always in the
background of the cohort characteristics. The findings of
this study based on the aggregated results from 42 caregivers
with children having asthma and/or wheezing condition can
be summarized as follows. Caregivers focused primarily on
the effectiveness of a treatment (episode-free days). Ranking
in terms of importance of expenses, availability of long-
term effects, and risk of exacerbation is strongly dependent
on the risk aversion of the caregiver.
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Glossary
Conjoint analysis: Was originally developed for market
research into consumer preferences, and is a method that
investigates the relative importance of groups of attributes,
eg, products with certain properties or more abstract
concepts such as treatment procedures.
Product attribute: Attributes are the characteristics of a
product, eg, side effects and costs.
Efficacy attribute: Attribute of the product related to the
efficacy. Here the efficacy is defined in the study below as
‘episode-free days’.
Attribute level: Specification of the product attribute.
Usually used by varying the characteristics within realistic
levels (eg, attributes for side effects could be low and strong
side effects)
Utility estimations: Utilities are a measurement about
the importance of a product and/or attribute to the
consumers. Usually a utility is a number between 0 and 100.
Base case: Analysis which is based on the dataset without
changing and/or including any assumptions (eg, Monte
Carlo simulation).
Beta-pert distribution:  Statistical distribution to assume
characteristics which are bound between the calculated
ranges of the parameters given by the study participants.
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Appendix
Appendix 1 An example of a card presented to respondents is shown in Table A1.
Appendix A.1: Example of a card presented to respondents
AGENT A AGENT B (SEE EXCEL)
Episode-free days 180 episode-free days per year 220 episode-free days per year
Exacerbation Risk of exacerbation: 10% of patients Risk of exacerbation: 16% of patients develop a mild to
develop a mild to severe exacerbation severe exacerbation
Information availability Information available on long-term effects Information available on long-term effects in children
in children between 4 years and 14 years between 4 years and 14 years of age
of age
Out-of-pocket expenses $20 $50
OO